Private equity specialists Bain Capital and Cinven inked a deal to purchase the Specialty Ingredients unit (LSI) of Switzerland-based pharmaceuticals group Lonza for an enterprise value of CHF4.2 billion ($4.7 billion) in a transaction that is set to close in the second half of this year.
According to Lonza Chairman Albert Baehny, Bain and Cinven have shown an understanding of the value of the experience and expertise of the company’s employees and presented the “most compelling industrial strategy and vision for the business” and are keen to prioritize R&D and innovation . . .
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators